CO2021002087A2 - Método para tratar la epilepsia - Google Patents
Método para tratar la epilepsiaInfo
- Publication number
- CO2021002087A2 CO2021002087A2 CONC2021/0002087A CO2021002087A CO2021002087A2 CO 2021002087 A2 CO2021002087 A2 CO 2021002087A2 CO 2021002087 A CO2021002087 A CO 2021002087A CO 2021002087 A2 CO2021002087 A2 CO 2021002087A2
- Authority
- CO
- Colombia
- Prior art keywords
- fenfluramine
- epileptic seizure
- racemate
- treatment
- less
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711051P | 2018-07-27 | 2018-07-27 | |
| PCT/US2019/043765 WO2020023923A1 (en) | 2018-07-27 | 2019-07-26 | Method for treating epilepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021002087A2 true CO2021002087A2 (es) | 2021-04-30 |
Family
ID=67551433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0002087A CO2021002087A2 (es) | 2018-07-27 | 2021-02-23 | Método para tratar la epilepsia |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20200030260A1 (enExample) |
| EP (1) | EP3829558B1 (enExample) |
| JP (1) | JP2021530541A (enExample) |
| KR (1) | KR20210061332A (enExample) |
| CN (1) | CN112930175A (enExample) |
| AU (1) | AU2019310600A1 (enExample) |
| BR (1) | BR112021001135A2 (enExample) |
| CA (1) | CA3106031A1 (enExample) |
| CL (1) | CL2021000196A1 (enExample) |
| CO (1) | CO2021002087A2 (enExample) |
| CR (1) | CR20210095A (enExample) |
| EA (1) | EA202190369A1 (enExample) |
| ES (1) | ES2988130T3 (enExample) |
| IL (1) | IL280128A (enExample) |
| MA (1) | MA53329A (enExample) |
| MX (1) | MX2021000987A (enExample) |
| PE (1) | PE20211065A1 (enExample) |
| PH (1) | PH12021550176A1 (enExample) |
| SG (1) | SG11202100682YA (enExample) |
| WO (1) | WO2020023923A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| SG11201804811WA (en) | 2015-12-22 | 2018-07-30 | Zogenix International Ltd | Fenfluramine compositions and methods of preparing the same |
| KR20180095674A (ko) | 2015-12-22 | 2018-08-27 | 조게닉스 인터내셔널 리미티드 | 대사 저항성 펜플루라민 유사체 및 그 사용 방법 |
| RU2746000C2 (ru) | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
| WO2020047312A1 (en) * | 2018-08-31 | 2020-03-05 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
| US12144787B2 (en) | 2018-11-19 | 2024-11-19 | Zogenix International Limited | Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5) |
| CN114127150A (zh) * | 2019-07-18 | 2022-03-01 | 巴斯夫欧洲公司 | 脲基甲酸酯基分散剂 |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| US20230078820A1 (en) * | 2021-09-01 | 2023-03-16 | Zogenix International Limited | Fenfluramine for treatment of demyelinating diseases and conditions |
| CN118873517A (zh) * | 2024-07-05 | 2024-11-01 | 上海柯西医药科技发展有限公司 | 大麻二酚与5-ht2b受体激动剂的组合的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL270984A (enExample) | 1960-11-05 | |||
| GB1175516A (en) | 1966-04-15 | 1969-12-23 | Science Union & Cie | New Phenyl-Aminopropane Derivatives and Preparations Containing them |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| WO1995033455A1 (en) * | 1994-06-03 | 1995-12-14 | Elmaleh David R | Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof |
| JP2001524124A (ja) | 1997-05-07 | 2001-11-27 | ガレン（ケミカルズ）リミティド | テストステロンおよびテストステロン前駆体の投与のための膣内薬物送達用具 |
| US6591909B1 (en) | 2001-12-20 | 2003-07-15 | Halliburton Energy Services, Inc. | Whey protein retarder |
| US9549909B2 (en) * | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| CA3204599A1 (en) * | 2015-02-25 | 2016-09-01 | The Regents Of The University Of California | 5ht agonists for treating disorders |
| JP6668045B2 (ja) * | 2015-05-15 | 2020-03-18 | ゾゲニクス インターナショナル リミテッド | ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト |
| JP2017057188A (ja) * | 2015-09-14 | 2017-03-23 | ゾゲニクス インターナショナル リミテッド | 特別な形態のてんかんの併用療法 |
| GB201715919D0 (en) * | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
-
2019
- 2019-07-26 MX MX2021000987A patent/MX2021000987A/es unknown
- 2019-07-26 KR KR1020217004603A patent/KR20210061332A/ko not_active Ceased
- 2019-07-26 CR CR20210095A patent/CR20210095A/es unknown
- 2019-07-26 US US16/523,568 patent/US20200030260A1/en active Pending
- 2019-07-26 CN CN201980049623.9A patent/CN112930175A/zh active Pending
- 2019-07-26 CA CA3106031A patent/CA3106031A1/en active Pending
- 2019-07-26 MA MA053329A patent/MA53329A/fr unknown
- 2019-07-26 JP JP2021503108A patent/JP2021530541A/ja active Pending
- 2019-07-26 BR BR112021001135-8A patent/BR112021001135A2/pt not_active IP Right Cessation
- 2019-07-26 ES ES19750214T patent/ES2988130T3/es active Active
- 2019-07-26 EA EA202190369A patent/EA202190369A1/ru unknown
- 2019-07-26 PE PE2021000089A patent/PE20211065A1/es unknown
- 2019-07-26 EP EP19750214.9A patent/EP3829558B1/en active Active
- 2019-07-26 AU AU2019310600A patent/AU2019310600A1/en not_active Abandoned
- 2019-07-26 SG SG11202100682YA patent/SG11202100682YA/en unknown
- 2019-07-26 WO PCT/US2019/043765 patent/WO2020023923A1/en not_active Ceased
-
2021
- 2021-01-12 IL IL280128A patent/IL280128A/en unknown
- 2021-01-22 PH PH12021550176A patent/PH12021550176A1/en unknown
- 2021-01-25 CL CL2021000196A patent/CL2021000196A1/es unknown
- 2021-02-23 CO CONC2021/0002087A patent/CO2021002087A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020023923A1 (en) | 2020-01-30 |
| CA3106031A1 (en) | 2020-01-30 |
| EA202190369A1 (ru) | 2021-06-10 |
| AU2019310600A1 (en) | 2021-02-11 |
| EP3829558C0 (en) | 2024-07-03 |
| MX2021000987A (es) | 2021-06-15 |
| CL2021000196A1 (es) | 2021-12-31 |
| CR20210095A (es) | 2021-06-01 |
| EP3829558B1 (en) | 2024-07-03 |
| ES2988130T3 (es) | 2024-11-19 |
| SG11202100682YA (en) | 2021-02-25 |
| JP2021530541A (ja) | 2021-11-11 |
| KR20210061332A (ko) | 2021-05-27 |
| IL280128A (en) | 2021-03-01 |
| MA53329A (fr) | 2022-03-02 |
| PE20211065A1 (es) | 2021-06-09 |
| EP3829558A1 (en) | 2021-06-09 |
| BR112021001135A2 (pt) | 2021-04-20 |
| CN112930175A (zh) | 2021-06-08 |
| US20200030260A1 (en) | 2020-01-30 |
| PH12021550176A1 (en) | 2021-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021002087A2 (es) | Método para tratar la epilepsia | |
| MX2022015613A (es) | Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental. | |
| MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
| CL2017002242A1 (es) | Método para tratar un tumor cerebral | |
| MX2021010193A (es) | Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales. | |
| CL2015001700A1 (es) | Tratamiento de trastornos del ritmo circadiano | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| MX2024003145A (es) | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. | |
| MX2020003182A (es) | Uso de cannabidiol para el tratamiento de epilepsia. | |
| DOP2017000268A (es) | Metodos y kits para tratar depresion | |
| BR112022004272A2 (pt) | Tratamento de prejuízo comportamental em encefalopatia epilética e desenvolvimental | |
| MX2019001036A (es) | Tratamiento y prevencion de los trastornos del sueño. | |
| CO2018004684A2 (es) | Métodos para tratar la epilepsia | |
| PH12020551427A1 (en) | Epinephrine spray formulations | |
| BR112018004680A2 (pt) | método de tratamento de distúrbios de desenvolvimento | |
| EA201791874A1 (ru) | Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| EA202091057A3 (ru) | Способы и композиции для лечения нарушений, ассоциированных со старением | |
| MX2022004257A (es) | Composicion farmaceutica y metodo para tratamiento de los trastornos convulsionales. | |
| BR112018005267A2 (pt) | processo para realizar fototerapia ou fotoestimulação de retina, e sistema para realizar fototerapia ou fotoestimulação de retina | |
| WO2018209022A3 (en) | Methods of treating neuropsychiatric disorders | |
| MX383323B (es) | Grelina para uso en el tratamiento de lesión del cerebro traumática leve. | |
| MX2021008903A (es) | Compuestos y usos de los mismos. | |
| CO2024011399A2 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa | |
| MX2023009600A (es) | Análogos de la oxa-ibogaína para el tratamiento de trastornos por consumo de sustancias. |